Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Debt (2017 - 2025)

Historic Total Debt for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $2.9 million.

  • Serina Therapeutics' Total Debt fell 7411.03% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 7411.03%. This contributed to the annual value of $18.1 million for FY2022, which is 3728.22% up from last year.
  • As of Q3 2025, Serina Therapeutics' Total Debt stood at $2.9 million, which was down 7411.03% from $11.2 million recorded in Q3 2024.
  • In the past 5 years, Serina Therapeutics' Total Debt registered a high of $33.0 million during Q2 2023, and its lowest value of $2.2 million during Q3 2023.
  • Its 5-year average for Total Debt is $13.4 million, with a median of $11.2 million in 2024.
  • Per our database at Business Quant, Serina Therapeutics' Total Debt tumbled by 8581.75% in 2023 and then surged by 40270.39% in 2024.
  • Over the past 5 years, Serina Therapeutics' Total Debt (Quarter) stood at $13.2 million in 2021, then skyrocketed by 37.28% to $18.1 million in 2022, then crashed by 87.76% to $2.2 million in 2023, then soared by 402.7% to $11.2 million in 2024, then crashed by 74.11% to $2.9 million in 2025.
  • Its Total Debt was $2.9 million in Q3 2025, compared to $11.2 million in Q3 2024 and $11.1 million in Q2 2024.